Chonluten
Also known as: EDG, Glu-Asp-Gly, T-34, Bronchial Bioregulator, Respiratory Peptide
EDG Tripeptide | Bronchial/Lung Bioregulator
Overview
Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD.
Key benefits
- Normalizes respiratory system function
- Regulates protein synthesis in lung tissue
- Inhibits inflammatory TNF production
- Restores lung alveolar tissues
- Maintains bronchial mucous membranes
- Supports antioxidant gene expression
- May slow cell aging (geroprotective)
- Modulates mucosal function
Mechanism of action
Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.
Molecular data
- Type
- Tripeptide bioregulator
- Half-life
- Minutes (short peptide); effects persist via epigenetic changes
Sequence
Glu-Asp-Gly
Indications
What the research community uses this compound for, with self-reported effectiveness.
Respiratory Support
Anti-Inflammatory
Anti-Aging
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 10-20 mg | Daily for 10-20 days | — |
| — | 10 mg | 2-3 cycles yearly | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 10-20 mg | Daily for 10-20 days | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 10 mg | Daily for 10 days | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Generally well-tolerated
- Minimal side effects reported
Rare side effects
- Allergic reactions (rare)
Contraindications
- Active respiratory emergencies (seek medical care)
- Known hypersensitivity
- Pregnancy or breastfeeding